Floatz logo
Floatz Rating
BB65/100
Confidence
Indicative
v0.2
Sponsor
Cerevel Therapeutics, LLC
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05610189CT.gov
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
—Completed———
NCT05581823CT.gov
Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants
—Completed———
NCT04760769CT.gov
Open-label Trial in Parkinson's Disease (PD)
—Completed———
NCT04542499CT.gov
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
—Completed———
NCT04295642CT.gov
A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease
—Completed———
NCT04223193CT.gov
Flexible-Dose Trial in Early Parkinson's Disease (PD)
—Completed———
NCT04201093CT.gov
Fixed-Dose Trial in Early Parkinson's Disease (PD)
—Completed———
NCT03185481CT.gov
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
—Terminated———
NCT02847650CT.gov
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
—Terminated———
NCT02687542CT.gov
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
—Terminated———
Show 3 more trials
NCT02373072CT.gov
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
—Completed———
NCT02224664CT.gov
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease
—Completed———
NCT07158827CT.gov
Expanded Access to Tavapadon
—Available———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Parkinson Disease

AssetSponsorPhaseRating
Tavapadon (this asset)Cerevel Therapeutics, LLCP3BB · 65
SafinamideZambon SpAP4A
Cvt-301Acorda TherapeuticsP3A
IstradefyllineGeorgetown UniversityP4BBB
RasagilineGuangzhou Henovcom Bioscience Co. Ltd.P4BBB
PardoprunoxAbbott ProductsP3BBB
OpicaponeBial - Portela C S.A.P4BBB
RopiniroleTitan PharmaceuticalsP4BBB
CarbidopaTanta UniversityP4BBB

+42 more in the Parkinson Disease cohort

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Tavapadon in Parkinson Disease. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/tavapadon-parkinson-disease

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →